Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Degarelix |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Degarelix | Firmagon | FE200486 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04989946 | Phase Ib/II | Degarelix Degarelix + Nivolumab + pTVG-AR Degarelix + pTVG-AR | Androgen Deprivation, With or Without pTVG-AR, and With or Without Nivolumab, in Patients With Newly Diagnosed, High-Risk Prostate Cancer | Recruiting | USA | 0 |
NCT02972060 | Phase II | Triptorelin Leuprolide Degarelix Goserelin Darolutamide | ODM-201 vs Androgen Deprivation Therapy in Hormone naive Prostate Cancer | Active, not recruiting | ITA | FRA | ESP | BEL | 0 |
NCT02489357 | Phase I | Degarelix Pembrolizumab | Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer | Completed | USA | 0 |
NCT04787744 | Phase II | Goserelin Degarelix Relugolix Nilutamide Triptorelin Histrelin acetate Docetaxel + Prednisone Leuprolide Apalutamide Abiraterone + Prednisone Flutamide Abiraterone + Methylprednisolone Bicalutamide Docetaxel Enzalutamide | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT) | Recruiting | USA | 0 |
NCT01674270 | Phase II | Bicalutamide Degarelix | Degarelix Neo-Adjuvant Radical Prostatectomy Trial | Completed | CAN | 0 |
NCT04455750 | Phase III | Enzalutamide Goserelin + Leuprolide Enzalutamide + Rucaparib Degarelix | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (CASPAR) | Active, not recruiting | USA | 0 |
NCT02560051 | Phase II | Degarelix Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole | Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer | Terminated | USA | 0 |
NCT03899077 | Phase II | Triptorelin Goserelin Degarelix Leuprolide Apalutamide | Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (SAVE) | Recruiting | BEL | 0 |
NCT02278185 | Phase II | Goserelin Degarelix Histrelin acetate Triptorelin Leuprolide Enzalutamide | Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02494713 | Phase II | Degarelix Estramustine Docetaxel Doxorubicin Ketoconazole | Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer | Terminated | USA | 0 |
NCT06378866 | Phase II | Degarelix Goserelin Darolutamide Relugolix Triptorelin Enzalutamide Histrelin acetate Abiraterone + Prednisone Leuprolide Apalutamide | Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE) | Recruiting | USA | 0 |
NCT02663908 | Phase III | Degarelix Leuprolide | A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease | Terminated | USA | SVK | POL | GRC | GBR | FRA | FIN | DEU | CZE | CAN | 2 |
NCT06282588 | Phase II | Docetaxel Leuprolide Degarelix Goserelin Triptorelin Darolutamide | Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) | Recruiting | BEL | 0 |
NCT02799706 | Phase III | Flutamide Degarelix Bicalutamide | Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer (PEGASUS) | Active, not recruiting | ITA | GBR | FRA | ESP | DNK | DEU | CHE | BEL | 0 |
NCT02020070 | Phase II | Ipilimumab Degarelix | Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy | Active, not recruiting | USA | 0 |
NCT03009981 | Phase III | Abiraterone + Apalutamide + Degarelix + Prednisone Apalutamide + Degarelix Degarelix | A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer | Active, not recruiting | USA | 0 |
NCT04301414 | Phase I | BMS-986218 + Degarelix Degarelix | Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P) | Active, not recruiting | USA | 0 |
NCT02346253 | Phase Ib/II | Leuprolide Triptorelin Degarelix Bicalutamide Goserelin | High-Dose Brachytherapy in Treating Patients With Prostate Cancer | Active, not recruiting | USA | 0 |
NCT01786265 | Phase II | Goserelin Degarelix Abiraterone Prednisone Leuprolide | Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone | Active, not recruiting | USA | 0 |
NCT06397703 | Phase III | Leuprolide Degarelix Relugolix | ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer | Recruiting | USA | 0 |
NCT03678025 | Phase III | Docetaxel Nilutamide Triptorelin Bicalutamide Leuprolide Degarelix Goserelin Flutamide Prednisone Abiraterone Histrelin acetate | Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Recruiting | USA | CHE | 3 |
NCT01751451 | Phase II | Abiraterone Degarelix | 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy | Completed | USA | 0 |
NCT02403505 | Phase II | Enzalutamide Abiraterone Prednisone Degarelix | Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms | Active, not recruiting | USA | 0 |
NCT05050084 | Phase III | Buserelin Relugolix Degarelix Goserelin Leuprolide Histrelin acetate Triptorelin Darolutamide + Goserelin Bicalutamide Darolutamide + Degarelix Darolutamide + Leuprolide Darolutamide + Triptorelin Buserelin + Darolutamide Darolutamide + Histrelin acetate Flutamide Darolutamide + Relugolix | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | Recruiting | USA | CAN | 0 |
NCT02472275 | Phase I | Leuprolide Pexidartinib Goserelin Degarelix | PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer | Completed | USA | 0 |
NCT04126070 | Phase II | Docetaxel + Nivolumab Leuprolide Goserelin Degarelix | Nivolumab + Docetaxel + ADT in Metastatic Hormone Sensitive Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03080116 | Phase II | Degarelix Apalutamide + Degarelix | Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy (ARNEO) | Active, not recruiting | BEL | 0 |